Oral ulcers encompass diverse conditions ranging from minor self-healing aphthous ulcers (accounting for 60-80% of oral ulceration) to serious manifestations of systemic disease requiring comprehensive investigation. Accurate diagnosis based on clinical characteristics, duration, size, distribution, and associated symptoms guides appropriate management, differentiating between minor mucosal trauma, infectious etiologies (herpes simplex, candidosis), inflammatory autoimmune conditions, and systemic disease manifestations.
Aphthous Ulcers: Minor Recurrent Form
Minor aphthous ulcers (also termed canker sores or aphthous stomatitis minor) represent the most common oral ulceration type, affecting 15-20% of the population at any given time. These ulcers appear as shallow round or oval lesions with yellow or white central fibrin base surrounded by erythematous halo. Size ranges from 2-8 millimeters, with multiple ulcers appearing simultaneously in approximately 50% of patients.
Development typically follows a predictable timeline: initial prodromal burning or tingling sensation 24 hours before visible ulceration, rapid ulcer development over 2-3 days, peak discomfort at 3-4 days, then gradual healing over 7-14 days. Ulcers heal by secondary intention (epithelialization from surrounding margins) without scar formation, distinguishing them from traumatic ulcers that may scar when deep.
Minor aphthous ulcers occur predominantly on moveable mucosa (buccal mucosa, ventral tongue, floor of mouth, soft palate margins) rather than keratinized tissues (hard palate, attached gingiva), a distribution pattern helping confirm the diagnosis. Etiology remains incompletely understood but involves complex immune response to oral bacterial antigens, with individual susceptibility determined by genetic factors and environmental triggers.
Recognized triggers include: minor trauma (toothbrush injury, accidental cheek biting, orthodontic bracket friction), sodium lauryl sulfate in toothpaste (sulfate-free toothpaste formulations show 80% reduction in recurrence in susceptible individuals), certain foods (spicy/acidic foods, citrus fruits, tomatoes), nutritional deficiencies (B12, folate, iron, zinc), stress and emotional factors, hormonal cycles (particularly mid-menstrual cycle and perimenstrually), and possible allergen exposure (particularly cinnamon, benzoates, and azo dyes in foods).
Nutritional assessment becomes essential if minor aphthous ulcers are frequent (more than 4-6 episodes annually). Serum vitamin B12, folate, iron, and zinc levels should be evaluated. Deficiency correction (through dietary modification or supplementation) substantially reduces ulcer frequency—some patients experiencing 80-90% reduction in recurrence after deficiency correction. Testing for celiac disease becomes warranted in patients with particularly high ulcer frequency, as untreated celiac disease leads to malabsorption and recurrent aphthous ulcers in 5-15% of celiac patients.
Major Aphthous Ulcers and Herpetiform Aphthous Ulcers
Major aphthous ulcers (aphthous ulcers major) represent severe ulceration >1 centimeter in diameter, often 1-3 centimeters, with deeper penetration than minor ulcers extending into the lamina propria. These ulcers cause severe pain disproportionate to their size, substantially impacting eating and speaking. Healing occurs over 2-4 weeks, frequently leaving visible scarring—an important clinical distinction from minor ulcers.
Major aphthous ulcers commonly occur on the soft palate, tonsillar pillars, and posterior pharynx rather than anterior oral mucosa. They represent only 5-10% of aphthous ulceration cases and warrant investigation for systemic causes. Herpetiform aphthous ulceration describes clusters of 10-100 tiny ulcers (0.5-1 millimeter) coalescing into larger lesions, showing clinical similarity to herpes simplex infection but occurring without viral infection (negative HSV PCR). Herpetiform ulcers follow similar etiology as other aphthous forms but show more aggressive recurrence and frequency, sometimes occurring nearly continuously without healing intervals.
Management of major aphthous ulcers involves more aggressive intervention than minor ulcer management. Intralesional corticosteroid injection (triamcinolone acetonide 40 mg/mL injected directly into or immediately surrounding the ulcer) reduces pain, accelerates healing, and prevents scar formation. Injection produces immediate pain relief in 50-70% of patients and reduced healing time from 3-4 weeks to 1-2 weeks. Multiple injections may be necessary if ulcers are large or multiple.
Topical corticosteroids (fluocinonide ointment, triamcinolone ointment) show modest benefit when applied directly to ulcer surfaces before healing, reducing pain and possibly accelerating healing by 2-3 days. Systemic corticosteroids (prednisone 20-40 mg daily tapered over 2-3 weeks) provide benefit for severe herpetiform ulceration or major ulcers refractory to other management, though adverse effects with long-term use limit this approach. Systemic therapies (azathioprine, pentoxifylline, colchicine) show benefit in published case series but lack robust randomized trial evidence.
Herpes Simplex Virus Stomatitis
Primary herpes simplex virus (HSV-1 and HSV-2) infection presents differently from aphthous ulcers, affecting 30-90% of the population by age 30, with 10-15% experiencing symptomatic primary infection (gingivostomatitis) and 20-40% experiencing recurrent herpes labialis. Primary HSV stomatitis presents with prodromal burning, then rapid development of vesicles on keratinized and non-keratinized mucosa, palate, and tongue. Vesicles rapidly rupture into shallow ulcers with red halo, yellow fibrin base, and clear demarcation.
Clinical characteristics distinguishing herpes from aphthous ulcers include: distribution on both moveable and keratinized tissues (including palate and attached gingiva), frequent gingival involvement (herpetic gingivitis with red, swollen, bleeding gingiva), multiple simultaneous ulcers in high clusters rather than sparse distribution, associated systemic symptoms (fever, lymphadenopathy, malaise in primary infection), and healing within 7-10 days without scar formation.
Diagnosis confirmation employs viral culture (gold standard for sensitivity/specificity), direct immunofluorescence with anti-HSV antibodies, or PCR detection. Tzanck smear (cytology revealing multinucleated giant cells) shows high sensitivity but lower specificity.
Antiviral therapy is most effective during prodromal phase (before vesicle rupture) and within 72 hours of symptom onset. Acyclovir (400 mg orally five times daily for 7-10 days for primary infection, or 400 mg three times daily for recurrent episodes) reduces healing time by 1-2 days and reduces pain severity. More convenient dosing regimens (valacyclovir 500 mg twice daily or famciclovir 250 mg three times daily) show comparable efficacy. For recurrent herpes labialis, patient-initiated therapy during prodromal phase substantially reduces progression to full vesicular eruption in 50-70% of cases.
Topical acyclovir ointment provides minimal benefit due to poor oral penetration and is generally not recommended. However, topical analgesics and protective ointments may provide symptomatic relief. Severe primary HSV stomatitis may warrant IV acyclovir (250 mg IV every 8 hours for 5-7 days) for immunocompromised patients.
Oral Candidiasis and Fungal Ulceration
Oral candidiasis (candida albicans infection) presents in multiple clinical forms: erythematous candidiasis (red, atrophic mucosa), pseudomembranous candidiasis (white plaques wiping away to reveal bleeding base), and angular cheilitis (cracks at mouth corners). Predisposing factors include: immunosuppression (HIV/AIDS, malignancy, immunosuppressive medications), broad-spectrum antibiotics (reducing competing bacteria), topical or systemic corticosteroids, xerostomia, diabetes, and poor oral hygiene.
Oral candidiasis doesn't typically cause frank ulceration but rather erythema, erosions, and plaques. When erosive changes occur (erosive candidiasis), they present as painful red ulcers. Diagnosis employs clinical appearance, KOH preparation showing pseudohyphae and blastoconidia, or fungal culture.
Antifungal therapy includes topical agents (nystatin suspension 100,000 units/mL swished 4-6 times daily for 7-14 days, or clotrimazole troches 10 mg dissolved 5 times daily) for localized infection, or systemic agents (fluconazole 100 mg daily for 7-14 days, or itraconazole 200 mg daily) for severe or refractory cases. Underlying predisposing conditions require concurrent management—xerostomia management, improved oral hygiene, diabetes control, or immunological intervention.
Traumatic Ulcers and Chemical Injury
Oral trauma from toothbrush injury, sharp foods (bone fragments, sharp chips), orthodontic bracket friction, or denture irritation produces ulcers showing distinctive clinical characteristics: clear traumatic history, ulcer location at site of trauma (often buccal mucosa), sharply demarcated borders sometimes with tissue maceration, absence of surrounding erythema (unlike infectious etiologies), and rapid healing (5-7 days) once traumatic source is removed.
Chemical ulceration from topical irritants (aspirin, hydrogen peroxide, ethanol, tobacco) produces similar patterns with history of chemical application and location at application site. Management requires removal of traumatic source and general supportive care—ulcers require no specific therapy beyond elimination of ongoing trauma.
Severe traumatic ulcers may warrant local anesthetic application (viscous lidocaine 2% applied topically before eating) for pain relief. Topical antibiotics prevent secondary bacterial infection, though systemic infection risk is minimal with adequate oral hygiene and intact immune function.
Systemic Disease Manifestations and Red Flags
Certain presentations warrant investigation for underlying systemic disease: large ulcers >1 centimeter, persistent ulcers remaining unhealed beyond 3 weeks, multiple simultaneous ulcers (>5-10 ulcers), ulcers with irregular borders or tissue destruction beyond typical ulcers, and ulcers accompanied by systemic symptoms (fever, rash, arthralgia, genital ulcers).
Behçet's disease presents with recurrent major ulcers accompanied by genital ulcers, eye involvement (usually uveitis), and skin lesions. Diagnosis requires ulcers in 3-4 locations (oral, genital, ocular, cutaneous) with at least 2 years of recurrent ulceration. Systemic corticosteroids and immunosuppressive agents become necessary for management.
Other systemic conditions causing oral ulceration include: pemphigoid (autoimmune bullous disease with erosive ulcers, often with gingival involvement), pemphigus vulgaris (intraepithelial blistering leading to ulceration), lichen planus (erosive form with lacy white patches and ulceration), and Crohn's disease (ulcers sometimes preceding GI disease manifestation).
Symptomatic Management and Topical Treatments
Relief of oral ulcer pain improves quality of life and nutritional intake. Topical anesthetics (viscous lidocaine 2%, benzocaine ointment) provide 15-30 minutes of mucosal anesthesia following application, sufficient to allow eating or speaking. Anesthetics should be applied just before eating to maximize benefit duration.
Antimicrobial rinses (chlorhexidine 0.12% twice daily or hydrogen peroxide rinses) reduce secondary bacterial infection and may slightly accelerate healing, though clinical benefit is modest. Most oral ulcers have minimal infection risk due to excellent oral blood supply and antimicrobial properties of saliva.
Protective barrier agents (amlexanox paste applied directly to ulcer surface three times daily) show modest healing acceleration (healing time reduced by 1-2 days) in some studies through unknown mechanisms. Cost-benefit analysis often favors supportive care and topical analgesics over prescription protective agents.
Laser therapy applied to painful recurrent aphthous ulcers (low-level laser at 980 nm wavelength, 1-2 watts power, approximately 30-60 seconds duration) shows promising results in small studies, with 50-70% of patients showing reduced pain and accelerated healing. Mechanism possibly involves stimulation of mitochondrial function and reduced inflammatory response. Further research is necessary to establish standardized protocols and compare cost-benefit to simpler topical approaches.